Abstract
Cancer Metabolism Cells use the same precursor to produce the essential amino acids methionine and cysteine. Lien et al. determined why human breast cancer cells with oncogenic mutations in the lipid kinase PI3K cannot produce methionine, a metabolic vulnerability called methionine dependency. Oncogenic PI3K mutants inhibited the expression and activity of xCT, a transporter that imports an oxidized form of cysteine, thereby limiting precursor availability for methionine synthesis. Thus, methionine restriction could potentially be used to treat breast tumors expressing oncogenic PI3K mutants. Sci. Signal. 10 , eaao6604 (2017).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
